SEHK:1952Biotechs
Everest Medicines Expands Partnerships To Broaden Pipeline And Future Cash Flows
In June, Everest Medicines (SEHK:1952) signed a global out licensing deal with Travere Therapeutics for its BTK inhibitor civorebrutinib (EVER001).
The company also agreed to acquire presbyopia therapy LNZ100 from Corxel Pharmaceuticals and secured a regional cardiovascular licensing partnership for Sumecigrel from Jiangsu Vcare PharmaTech.
Together, these transactions expand Everest Medicines' pipeline in nephrology, ophthalmology and cardiovascular disease while widening its collaboration...